India, July 21 -- Alpha Tau Medical Ltd. (DRTS) announced positive results from a clinical study evaluating Alpha DaRT in combination with pembrolizumab (Keytruda) in elderly patients with locally advanced and metastatic head and neck squamous cell carcinoma (HNSCC).
The results showed a 100% objective response rate (ORR) and a median overall survival of 18.2 months among nine evaluable patients.
Head and neck cancer is among the most common cancers worldwide, with an estimated 890,000 new cases diagnosed each year globally, as per company estimates.
Trial Details
Alpha Tau's study is a single-center, prospective, open-label, single-arm study evaluating Alpha DaRT in combination with pembrolizumab in up to 48 patients with recurrent unr...